Sanofi is re-entering the T-cell engager (TCE) space through a deal that will see it pay $180 million upfront and in near-term payments for a phase 1 trispecific antibody developed by Kali Therapeutics.
The California-based biotech recently advanced the therapy, known as KT501, into a first-in-human study involving patients with rheumatoid arthritis, as per the federal clinical trials database. The candidate is engineered to target CD3, BCMA and CD19, and Sanofi is aiming to explore its potential across a broad range of B-cell-driven autoimmune conditions.
Under the agreement, Kali will receive the $180 million in upfront and short-term payments, along with the opportunity to earn up to $1.05 billion in growth and marketing milestones. The deal also includes tiered royalties tied to future product sales.
KT501 was created using Kali’s protein engineering platform to achieve strong binding affinity across its three targets while reducing the risk of cytokine release syndrome, a potentially severe side effect associated with T cell–redirecting therapies.
In preclinical studies, the therapy showed robust depletion of B cells in both circulating blood and tissue, while also significantly lowering cytokine production, according to Kali’s March 23 announcement.
Weihao Xu, CEO of Kali, said in a statement that treating autoimmune conditions demands therapies that combine strong effectiveness with an improved safety profile, adding that KT501 represents a meaningful advance in that context. He added that by targeting a wide spectrum of B cell populations while limiting cytokine release, KT501 has the potential to meet important gaps in care for patients with autoimmune diseases.
Sanofi is well acquainted with T-cell engagers, a drug class that continues to draw strong interest in pharmaceutical dealmaking this year. The company previously acquired TCE-focused Amunix for $1 billion in 2021 but later divested three clinical-stage TCE assets to Vir Biotechnology in 2024.
Even so, Sanofi has continued to signal interest in TCEs as a therapeutic approach, despite not currently listing any such candidates within its active pipeline.
The renewed focus comes as the company works toward its goal of becoming a leader in immunoscience, following a series of clinical setbacks last year that contributed to the recent departure of former CEO Paul Hudson.
Meanwhile, Kali Therapeutics – named after the Hindu goddess Kali – has two additional T-cell engager programs in development. These include another trispecific antibody candidate and KT502, a CD19-targeting therapy the company aims to bring into clinical testing in the first half of the year.
Sanofi has also recently broadened its external innovation strategy, including collaborations with AI-driven discovery platforms aimed at speeding up biologics development. Before this latest agreement, the company participated in a major investment in Earendil Labs to support its AI-enabled biologics pipeline, highlighting a growing focus on combining advanced discovery technologies with large-scale development capabilities.
These types of partnerships can help connect early-stage innovation with the expertise required for late-stage development, potentially accelerating progress for complex biologics such as multi-specific antibodies across a range of therapeutic areas.
v Strategic Focus on Autoimmune Diseases
Autoimmune conditions, where the immune system mistakenly attacks healthy cells, remain a challenging area for treatment. Through this collaboration, v both companies aim to leverage advanced research platforms and scientific expertise to develop targeted therapies that can improve patient outcomes. The agreement reflects v growing demand for more effective and personalized treatments in this space.
v Financial Scope and Development Goals
The deal, exceeding $1 billion in total value, includes upfront payments, milestone-based incentives, and potential royalties. This structure allows v both partners to share risks and rewards while accelerating the development pipeline. The collaboration is expected to focus on next-generation therapies that address unmet medical needs in autoimmune disorders.
v Sanofi and Kali Partner for Autoimmune Innovation
Sanofi has entered into a major collaboration with Kali in a deal valued at over $1 billion to advance new autoimmune therapies. This partnership highlights how v global pharma companies are increasingly investing in cutting-edge biotech innovations to tackle complex immune-related diseases.
